Mesoblast limited (ADR) (MESO) is Downgraded by Credit Suisse to Neutral

Mesoblast limited (ADR) (MESO) was Downgraded by Credit Suisse to ” Neutral”. Earlier the firm had a rating of “Outperform ” on the company shares. Credit Suisse advised their investors in a research report released on Jun 14, 2016.

Many Wall Street Analysts have commented on Mesoblast limited (ADR). Shares were Reiterated by Maxim Group on May 10, 2016 to “Buy” and Lowered the Price Target to $ 14 from a previous price target of $18 .

Mesoblast Limited is engaged in the development of adult stem cell technology platform for commercialization. The Company develops a portfolio of regenerative therapeutic cell-based products. Its portfolio of therapeutic products is being developed using its technology platforms which include specialized cells known as mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs including cardiac diseases spine and musculoskeletal disorders oncology and hematology diseases and immune-mediated and inflammatory conditions. Its products have been prioritized into two tiers: tier 1 product candidates which represents its lead programs where it focuses on time and resources such as MPC-06-ID MPC-150-IM JR-031 MPC-300-IV and MSC-100-IV and tier 2 product candidates which advances to tier 1 depending on newly-generated data market opportunity or partnering options such as MSC-100-IV MPC-25-IC MPC-25-Osteo and MPC-CBE.

Mesoblast limited (ADR)

Leave a Reply

Mesoblast limited (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mesoblast limited (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.